Trexquant Investment LP Puma Biotechnology, Inc. Transaction History

Trexquant Investment LP

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.92 - $5.83 $1,369 - $2,734	469 Added 1.46%	32,668 $106,000
Q1 2024 May 14, 2024	BUY	$4.29 - $7.4 $138,133 - $238,272	32,199 New	32,199 $170,000
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $79,044 - $182,496	-27,735 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$6.63 - $9.39 $25,160 - $35,635	-3,795 Reduced 12.04%	27,735 $194,000
Q2 2021 Aug 12, 2021	BUY	$8.98 - $11.6 $283,139 - $365,748	31,530 New	31,530 $289,000
Q4 2020 Feb 11, 2021	SELL	$7.78 - $12.13 $104,570 - $163,039	-13,441 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$9.5 - $11.14 $127,689 - $149,732	13,441 New	13,441 $136,000
Q2 2020 Aug 07, 2020	SELL	$7.01 - $13.24 $554,140 - $1.05 Million	-79,050 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$6.28 - $14.57 $306,859 - $711,933	48,863 Added 161.87%	79,050 $667,000
Q4 2019 Feb 12, 2020	SELL	$6.5 - $10.73 $119,073 - $196,562	-18,319 Reduced 37.77%	30,187 $264,000
Q3 2019 Nov 08, 2019	BUY	$8.75 - $12.85 $424,427 - $623,302	48,506 New	48,506 $522,000
Q2 2019 Aug 09, 2019	SELL	$12.3 - $35.76 $804,789 - $2.34 Million	-65,430 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$20.77 - $42.37 $1.36 Million - $2.77 Million	65,430 New	65,430 $2.54 Million
Q4 2018 Feb 13, 2019	SELL	$20.07 - $46.7 $492,297 - $1.15 Million	-24,529 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$41.2 - $59.85 $1.01 Million - $1.47 Million	24,529 New	24,529 $1.13 Million
Q2 2018 Aug 07, 2018	SELL	$48.3 - $68.25 $448,272 - $633,428	-9,281 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$59.7 - $99.25 $554,075 - $921,139	9,281 New	9,281 $632,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.